 Business Update
June 10, 2024
Four Corners Property Trust Expands Portfolio with Acquisition of MercyOne Outpatient Clinic for $3 Million MILL VALLEY, Calif. Four Corners Property Trust (NYSE: FCPT), a leading real estate investment trust renowned for its portfolio of high-quality, net-leased restaurant and retail properties, has announced a s...
|
Business Update
June 10, 2024
Granting Leverage: Kezar Life Sciences Fosters Growth with Strategic Inducement Grant Kezar Life Sciences, Inc.: Driving Innovation in Immune-Mediated Diseases and Cancer Therapeutics Kezar Life Sciences, Inc. (Nasdaq: KZR) recently announced an inducement grant under NASDAQ Listing Rule 5635(c)(4), signifying a...
|
Business Update
June 10, 2024
Virgin Galactic Achieves 12th Successful Spaceflight: A Leap Forward in Space-Based ResearchOrange County, Calif. February 2024 marks another historic milestone for Virgin Galactic Holdings, Inc. (NYSE: SPCE), as the company announced the completion of its second spaceflight of the year and its 12th mission overa...
|
|
 Partnership
June 10, 2024
Virginia City, NV, June 10, 2024 Comstock Inc. (NYSE: LODE), widely known for its innovative environmental technologies, has announced significant advancements in their ongoing partnership with RenFuel K2B AB (RenFuel). This progress involves amended agreements about the development of RenFuel’s pre-existing, p...
 Product Service News
June 10, 2024
Zymeworks Achieves Key Milestones in Global Development: NMPA Acceptance of BLA for Zanidatamab in China and Inclusion in Nasdaq Biotechnology Index VANCOUVER, British Columbia, June 10, 2024 Zymeworks Inc. (Nasdaq: ZYME), a pioneering clinical-stage biotechnology company, is making significant strides in advancing...
|
|
Our most Popular Articles
|
Product Service News
April 4, 2024
Grifols Procleix ArboPlex Assay Revolutionizes Arbovirus Screening: First 4-in-1 NAT to Receive CE MarkBARCELONA, Spain - Grifols, a global leader in plasma-derived medicines and diagnostic solutions, has recently achieved a significant milestone in the field of arbovirus screening. The company announced that its gr...
|
Clinical Study
:'
Alpha Tau Medical Ltd., a company specializing in breakthrough cancer treatments using Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), has released compelling data in 'Cancers Journal' from four international clinical trials targeting various hard-to-treat superficial cancers. The findings offer promising long-term safety and efficacy profiles, potentially positioning Alpha Tau as a leader in the oncological treatment space.
Background:'
The landscape of cancer treatment has been continually evolving with innovative approaches aimed at increasing the efficacy and safety of therapies. Superficial cancers, including those affecting the skin, head, and neck, as well as the oral cavity, are notoriously difficult to treat due to their accessibility and potential disfigurement caused by conventional treatments. Alpha Tau’s Alpha DaRT technology represents a novel method, leveraging the power of alpha radiation to selectively target malignant cells while sparing the surrounding healthy tissue.
Clinical Trials and Data Analysis:'
The recent publication in 'Cancers Journal' consolidates data from four international clinical trials which spanned different superficial cancer indications. These trials were designed to evaluate both the long-term safety and efficacy of Alpha DaRT across various patient cohorts.
'Patient Cohorts:' The pooled analysis incorporated patients with skin, head & neck, and oral cavity cancers, highlighting the technology's versatile application across these challenging areas.
'Treatment Procedures:' The Alpha DaRT treatment involved inserting radium-loaded wires into the tumor mass, where they emitted alpha particles that selectively destroy cancerous cells.
'Safety Profile:' Throughout the long-term follow-up, patients exhibited minimal adverse effects, affirming the treatment's favorable safety profile accustomed to the targeted nature of alpha radiation.
'Efficacy:' The findings underscored significant efficacy, with notable tumor shrinkage and, in some cases, complete regression observed across patient cohorts.
Impact on Alpha Tau:'
The release of these long-term safety and efficacy data is not just a milestone for patients and the medical community, but also a strategic victory for Alpha Tau. Here's how:
'Reputation as a Pioneer:' The publication solidifies Alpha Tau's reputation as a pioneering force in the cancer treatment arena, with its technology demonstrating tangible, positive patient outcomes.
'Investor Confidence:' Robust clinical data can significantly boost investor confidence, potentially leading to increased funding and valuation.
'Regulatory Approval Pathway:' The positive outcomes pave the way for smoother regulatory approvals, as long-term safety and efficacy are critical considerations for agencies like the FDA.
'Market Penetration:' With such compelling data, Alpha Tau is well-positioned to accelerate its market penetration strategy, making its technology accessible to a broader patient population worldwide.
Conclusion:'
Alpha Tau’s Alpha DaRT technology showcases a remarkable innovation in the treatment of superficial cancers with promising long-term safety and efficacy. This development heralds a new era in oncology, offering hope to patients with few existing options. For Alpha Tau, the positive clinical trial outcomes not only reinforce its cutting-edge approach but also pave the way for substantial advances in cancer treatment.
June 25, 2024
: Alpha Tau Medical Ltd., a company specializing in breakthrough cancer treatments using Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), has released compelling data in Cancers Journal from four international clinical trials targeting various hard-to-treat superficial cancers. The findings offer promising...
|
Management Announcement
September 5, 2024
EHang Strongly Refutes False Allegations, Clarifies Misinformation Causing Stock Volatility
GUANGZHOU, China, Sept. 04, 2024 - EHang Holdings Limited (EHang or the Company) (Nasdaq: EH), the world s leading urban air mobility (UAM) technology platform company, today strongly refuted recent unfounded rumors cir...
|
|
|
Company News
|
Business Update
June 10, 2024
Granting Leverage: Kezar Life Sciences Fosters Growth with Strategic Inducement Grant Kezar Life Sciences, Inc.: Driving Innovation in Immune-Mediated Diseases and Cancer Therapeutics Kezar Life Sciences, Inc. (Nasdaq: KZR) recently announced an inducement grant under NASDAQ Listing Rule 5635(c)(4), signifying a...
|
Business Update
June 10, 2024
Virgin Galactic Achieves 12th Successful Spaceflight: A Leap Forward in Space-Based ResearchOrange County, Calif. February 2024 marks another historic milestone for Virgin Galactic Holdings, Inc. (NYSE: SPCE), as the company announced the completion of its second spaceflight of the year and its 12th mission overa...
|
Business Update
June 10, 2024
Americanas Group Partners with Rimini Street to Overhaul and Elevate SAP Operations LAS VEGAS Rimini Street, Inc. (Nasdaq: RMNI), a distinguished global provider of comprehensive enterprise software support, products, and services, has announced a significant partnership with Americanas Group. This collaboration...
|
|
|
Company News
 Announcement
June 10, 2024
|
Company News
 Product Service News
June 10, 2024
|
Company News
 Business Update
June 9, 2024
|
More Company News
|
Business Update
June 9, 2024
|
Business Update
June 9, 2024
|
Business Update
June 9, 2024
|
Business Update
June 9, 2024
|
Clinical Study
June 9, 2024
|
Business Update
June 8, 2024
|
Announcement
June 8, 2024
|
Announcement
June 8, 2024
|
Announcement
June 8, 2024
|
Announcement
June 8, 2024
|
|
|
|
Related News
|
Business Update
|
Business Update
|
|
Stocks
|
Business Update
|
Business Update
|
Business Update
|
|
|
|
Business News
|
 Partnership
Virginia City, NV, June 10, 2024 Comstock Inc. (NYSE: LODE), widely known for its innovative environmental technologies, has announced significant advancements in their ongoing partnership with RenFuel K2B AB (RenFuel). This progress involves amended agreements about the development of RenFuel’s pre-existing, p...
|
|
Product Service News
Zymeworks Achieves Key Milestones in Global Development: NMPA Acceptance of BLA for Zanidatamab in China and Inclusion in Nasdaq Biotechnology Index VANCOUVER, British Columbia, June 10, 2024 Zymeworks Inc. (Nasdaq: ZYME), a pioneering clinical-stage biotechnology company, is making significant strides in advancing...
|
 Clinical Study
Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab: A Novel Precision Medicine Strategy to Transform Dry Eye Disease Treatment Groundbreaking Outcomes Could Revolutionize Dry Eye Disease Management ZUG, Switzerland, June 10, 2024 Oculis Holding AG (Nasdaq: OCS), a pioneering globa...
|
 Business Update
Gossamer Bio s Strategic Moves in the Face of Market Expectations San Diego-based Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company, has recently made significant strides in its journey focused on the development and commercialization of seralutinib for treating pulmonary arterial hyperte...
|
 Business Update
Four Corners Property Trust Expands Portfolio with Acquisition of MercyOne Outpatient Clinic for $3 Million MILL VALLEY, Calif. Four Corners Property Trust (NYSE: FCPT), a leading real estate investment trust renowned for its portfolio of high-quality, net-leased restaurant and retail properties, has announced a s...
|
Our Most Popular Articles
|
|
Product Service News
Grifols Procleix ArboPlex Assay Revolutionizes Arbovirus Screening: First 4-in-1 NAT to Receive CE MarkBARCELONA, Spain - Grifols, a global leader in plasma-derived medicines and diagnostic solutions, has recently achieved a significant milestone in the field of arbovirus screening. The company announced that its gr...
|
 Clinical Study
:'
Alpha Tau Medical Ltd., a company specializing in breakthrough cancer treatments using Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), has released compelling data in 'Cancers Journal' from four international clinical trials targeting various hard-to-treat superficial cancers. The findings offer promising long-term safety and efficacy profiles, potentially positioning Alpha Tau as a leader in the oncological treatment space.
Background:'
The landscape of cancer treatment has been continually evolving with innovative approaches aimed at increasing the efficacy and safety of therapies. Superficial cancers, including those affecting the skin, head, and neck, as well as the oral cavity, are notoriously difficult to treat due to their accessibility and potential disfigurement caused by conventional treatments. Alpha Tau’s Alpha DaRT technology represents a novel method, leveraging the power of alpha radiation to selectively target malignant cells while sparing the surrounding healthy tissue.
Clinical Trials and Data Analysis:'
The recent publication in 'Cancers Journal' consolidates data from four international clinical trials which spanned different superficial cancer indications. These trials were designed to evaluate both the long-term safety and efficacy of Alpha DaRT across various patient cohorts.
'Patient Cohorts:' The pooled analysis incorporated patients with skin, head & neck, and oral cavity cancers, highlighting the technology's versatile application across these challenging areas.
'Treatment Procedures:' The Alpha DaRT treatment involved inserting radium-loaded wires into the tumor mass, where they emitted alpha particles that selectively destroy cancerous cells.
'Safety Profile:' Throughout the long-term follow-up, patients exhibited minimal adverse effects, affirming the treatment's favorable safety profile accustomed to the targeted nature of alpha radiation.
'Efficacy:' The findings underscored significant efficacy, with notable tumor shrinkage and, in some cases, complete regression observed across patient cohorts.
Impact on Alpha Tau:'
The release of these long-term safety and efficacy data is not just a milestone for patients and the medical community, but also a strategic victory for Alpha Tau. Here's how:
'Reputation as a Pioneer:' The publication solidifies Alpha Tau's reputation as a pioneering force in the cancer treatment arena, with its technology demonstrating tangible, positive patient outcomes.
'Investor Confidence:' Robust clinical data can significantly boost investor confidence, potentially leading to increased funding and valuation.
'Regulatory Approval Pathway:' The positive outcomes pave the way for smoother regulatory approvals, as long-term safety and efficacy are critical considerations for agencies like the FDA.
'Market Penetration:' With such compelling data, Alpha Tau is well-positioned to accelerate its market penetration strategy, making its technology accessible to a broader patient population worldwide.
Conclusion:'
Alpha Tau’s Alpha DaRT technology showcases a remarkable innovation in the treatment of superficial cancers with promising long-term safety and efficacy. This development heralds a new era in oncology, offering hope to patients with few existing options. For Alpha Tau, the positive clinical trial outcomes not only reinforce its cutting-edge approach but also pave the way for substantial advances in cancer treatment.
: Alpha Tau Medical Ltd., a company specializing in breakthrough cancer treatments using Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), has released compelling data in Cancers Journal from four international clinical trials targeting various hard-to-treat superficial cancers. The findings offer promising...
|
 Management Announcement
EHang Strongly Refutes False Allegations, Clarifies Misinformation Causing Stock Volatility
GUANGZHOU, China, Sept. 04, 2024 - EHang Holdings Limited (EHang or the Company) (Nasdaq: EH), the world s leading urban air mobility (UAM) technology platform company, today strongly refuted recent unfounded rumors cir...
|
More News
|
 Business Update
Granting Leverage: Kezar Life Sciences Fosters Growth with Strategic Inducement Grant Kezar Life Sciences, Inc.: Driving Innovation in Immune-Mediated Diseases and Cancer Therapeutics Kezar Life Sciences, Inc. (Nasdaq: KZR) recently announced an inducement grant under NASDAQ Listing Rule 5635(c)(4), signifying a...
|
 Business Update
Virgin Galactic Achieves 12th Successful Spaceflight: A Leap Forward in Space-Based ResearchOrange County, Calif. February 2024 marks another historic milestone for Virgin Galactic Holdings, Inc. (NYSE: SPCE), as the company announced the completion of its second spaceflight of the year and its 12th mission overa...
|
 Business Update
Americanas Group Partners with Rimini Street to Overhaul and Elevate SAP Operations LAS VEGAS Rimini Street, Inc. (Nasdaq: RMNI), a distinguished global provider of comprehensive enterprise software support, products, and services, has announced a significant partnership with Americanas Group. This collaboration...
|
 Announcement
Major Law Firms Alert Investors: Class Action Lawsuits Against Biogen, Charge Enterprises, and Fastly Deadlines LoomingNew York, June 9, 2024 Bragar Eagel & Squire, P.C., a nationally-recognized shareholder rights law firm, has formally reminded investors that class action lawsuits have been filed against three p...
|
 Product Service News
FDA Accepts Eisai s sBLA for LEQEMBI IV Maintenance Dosing Amidst Biogen s Market Challenges TOKYO and CAMBRIDGE, Mass., June 9, 2024 - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, Eisai) and Biogen Inc. (Nasdaq: BIIB, Corporate Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher) t...
|
 Business Update
In a move set to bolster its workforce and strengthen its ongoing research efforts, Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company, recently announced the Compensation Committee of its Board of Directors approved an inducement grant. Effective June 5, 2024, the grant includes a non-qua...
|
 Business Update
In the commercial real estate market, the strategic maneuvering of Four Corners Property Trust (NYSE: FCPT) reveals a calculated diversification that could bolster its portfolio s resilience and long-term growth potential. FCPT, renowned for its focus on high-quality, net-leased restaurant and retail properties, has...
|
 Business Update
Kezar Life Sciences: Strategic Inducement Grant and Q1 2024 Financial Highlights Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company specializing in innovative small molecule therapeutics to address substantial unmet needs in immune-mediated diseases and cancer, continues to make signific...
|
 Business Update
Virgin Galactic: Pioneering the Future with a Record 12th Spaceflight Virgin Galactic Holdings, Inc. (NYSE: SPCE), a leader in commercial space travel, announced the triumph of its 12th spaceflight, the company’s second mission in 2024. The success of the Galactic 07 flight continues to reinforce Virgin Galactic s...
|
 Business Update
Las Vegas Rimini Street, Inc. (Nasdaq: RMNI), a leading global provider of comprehensive enterprise software support services, announced today that Americanas Group has selected Rimini Street and its suite of Rimini Manage services for SAP to oversee, control, and manage their extensive, complex, and continually e...
|
 Clinical Study
At this year s Clinical Trials at the Summit 2024 in Park City, Utah, the spotlight was on 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company. 4DMT presented compelling new subgroup analyses from the Phase 2 PRISM trial evaluating their innovative treatm...
|
 Business Update
Riding the Wave of Success: Virgin Galactic’s 12th Spaceflight Marks a Milestone in Space Tourism and Research In a landmark achievement for both the aerospace industry and space tourism, Virgin Galactic has successfully completed its 12th spaceflight, dubbed Galactic 07. Held on a crisp morning in Orange County, ...
|
 Announcement
New York, June 8, 2024 Rosen Law Firm, a globally recognized investor rights law firm, has issued a call to action for investors in Enphase Energy, Inc. (NASDAQ: ENPH) seeking legal counsel. The notice pertains to a recently filed class action lawsuit on behalf of those who purchased Enphase Energy securities between February 7, 2023, and April 25, 2023. Interested parties aiming to serve as lead plaintiffs must submit their applications to the court by July 29, 2024. Key Takeaways- Class Action Lawsuit: A class action complaint has been filed against Enphase Energy, Inc.
|
 Announcement
Investors Urged to Take Immediate Action Amidst Turbulent Equinix Securities Class ActionIn a gripping turn of events, Equinix, Inc., the renowned digital infrastructure giant, finds itself amid a fierce legal storm. Multiple esteemed law firms, each with their own s, have called for investors to secure counsel as ...
|
 Announcement
Two prominent law firms have announced class action lawsuits against Exscientia p.l.c (NASDAQ: EXAI), urging investors who purchased securities between March 23, 2022, and February 12, 2024, to seek legal counsel before approaching deadlines.On June 8, 2024, the Rosen Law Firm, recognized globally for representing i...
|
 Announcement
Rosen Law Firm Encourages Globe Life Inc. Investors to Secure Counsel Before Upcoming Deadline in Securities Class Action NEW YORK, June 8, 2024 Rosen Law Firm, an esteemed global investor rights law firm, is urging investors who purchased common stock of Globe Life Inc., formerly known as Torchmark Corporation (NY...
|
|
|
|
|
